Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies
Open accessThe DOI matches its Crossref record; 153 of the 156 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Incomplete adherence to tuberculosis (TB) treatment increases the risk of delayed culture conversion with continued transmission in the community, as well as treatment failure, relapse, and development or amplification of drug resistance. We conducted a systematic review and meta-analysis of adherence interventions, including directly observed therapy (DOT), to determine which approaches lead to improved TB treatment outcomes. METHODS AND FINDINGS: We systematically reviewed Medline as well as the references of published review articles for relevant studies of adherence to multidrug treatment of both drug-susceptible and drug-resistant TB through February 3, 2018. We included randomized controlled trials (RCTs) as well as prospective and retrospective cohort studies (CSs) with an internal or external control group that evaluated any adherence intervention and conducted a meta-analysis of their impact on TB treatment outcomes. Our search identified 7,729 articles, of which 129 met the inclusion criteria for quantitative analysis. Seven adherence categories were identified, including DOT offered by different providers and at various locations, reminders and tracers, incentives and enablers, patient education, digital technologies (short message services [SMSs] via mobile phones and video-observed therapy [VOT]), staff education, and combinations of these interventions. When compared with DOT alone, self-administered therapy (SAT) was associated with lower rates of treatment success (CS: risk ratio [RR] 0.81, 95% CI 0.73-0.89; RCT: RR 0.94, 95% CI 0.89-0.98), adherence (CS: RR 0.83, 95% CI 0.75-0.93), and sputum smear conversion (RCT: RR 0.92, 95% CI 0.87-0.98) as well as higher rates of development of drug resistance (CS: RR 4.19, 95% CI 2.34-7.49). When compared to DOT provided by healthcare providers, DOT provided by family members was associated with a lower rate of adherence (CS: RR 0.86, 95% CI 0.79-0.94). DOT delivery in the community versus at the clinic was associated with a higher rate of treatment success (CS: RR 1.08, 95% CI 1.01-1.15) and sputum conversion at the end of two months (CS: RR 1.05, 95% CI 1.02-1.08) as well as lower rates of treatment failure (CS: RR 0.56, 95% CI 0.33-0.95) and loss to follow-up (CS: RR 0.63, 95% CI 0.40-0.98). Medication monitors improved adherence and treatment success and VOT was comparable with DOT. SMS reminders led to a higher treatment completion rate in one RCT and were associated with higher rates of cure and sputum conversion when used in combination with medication monitors. TB treatment outcomes improved when patient education, healthcare provider education, incentives and enablers, psychological interventions, reminders and tracers, or mobile digital technologies were employed. Our findings are limited by the heterogeneity of the included studies and lack of standardized research methodology on adherence interventions. CONCLUSION: TB treatment outcomes are improved with the use of adherence interventions, such as patient education and counseling, incentives and enablers, psychological interventions, reminders and tracers, and digital health technologies. Trained healthcare providers as well as community delivery provides patient-centered DOT options that both enhance adherence and improve treatment outcomes as compared to unsupervised, SAT alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



























Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The consequences of poor adherence include delayed sputum culture conversion, treatment failure, relapse, prolonged infectiousness, development of drug resistance, and increased morbidity and mortality [4,5].”
From Psychosocial Interventions for Improving Treatment Adherence in Tuberculosis Patients: A Scoping Review of Evidence-Based Approaches. (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous research has indicated that treatment adherence interventions (eg, patient counselling and education, reminders, and digital health technologies)47, 48 and social protection interventions (eg, cash transfers and economic incentives)49, 50 can increase treatment adherence and prevent mortality.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
(2014) · Medical Entomology and Zoology · Cited by 17,633
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
Free, C., Phillips, G., Galli, L., Watson, L., Felix, L., Edwards, P., Patel, V., & Haines, A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001362 · Cited by 1,766 · cited 1×
“Psychological interventions aim to support via psychological or emotional counseling or a social network of peers undergoing TB treatment as a means of improving adherence to TB treatment [18,19].”
BackgroundNahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw376 · Cited by 1,170
Self-citationPatient Adherence to Tuberculosis Treatment: A Systematic Review of Qualitative Research
Munro, S. A., Lewin, S. A., Smith, H. J., Engel, M. E., Fretheim, A., & Volmink, J. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040238 · Cited by 1,080
Assessing the Gold Standard — Lessons from the History of RCTs
Bothwell, L. E., Greene, J. A., Podolsky, S. H., & Jones, D. S. (2016) · New England Journal of Medicine · doi:10.1056/nejmms1604593 · Cited by 664
Directly observed therapy for treating tuberculosis
Karumbi, J., & Garner, P. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003343.pub4 · Cited by 644
The Effect of Directly Observed Therapy on the Rates of Drug Resistance and Relapse in Tuberculosis
Weis, S. E., Slocum, P. C., Blais, F. X., King, B., Nunn, M., Matney, G. B., Gomez, E., & Foresman, B. H. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404283301702 · Cited by 589 · cited 2×
“Only three CSs compared the impact of DOT on the development of drug resistance compared with SAT, one of which found no significant difference [4,59,70].”
BackgroundResultOrenstein, E. W., Basu, S., Shah, N. S., Andrews, J. R., Friedland, G. H., Moll, A. P., Gandhi, N. R., & Galvani, A. P. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70041-6 · Cited by 540
Research works printed but not linked: 7
- Alipanah N, Jarlsberg L, Miller C, Lechner A, Wai K, Nahid P. Report for Systematic Review for Adherence Interventions in TB Treatment. World Health Organization guidelines for treatment of drug-susceptible tuberculosis and patient care. 2017;Annex 5.
- 2014, Review Manager (RevMan)
- T Chennai, 1997, A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis, Tuberculosis Research Centre. Int J Tuberc Lung Dis, 1, 509
- AA Vieira, 2011, Compliance with tuberculosis treatment after the implementation of the directly observed treatment, short-course strategy in the city of Carapicuiba, Brazil, J Bras Pneumol, 37, 223
- VK Arora, 2003, Community mediated domiciliary DOTS execution—A study from New Delhi, Ind J Tub, 50, 143
- JP Cantalice Filho, 2009, Food baskets given to tuberculosis patients at a primary health care clinic in the city of Duque de Caxias, Brazil: effect on treatment outcomes, J Bras Pneumol, 35, 992
- RP Paramasivan, 1993, Short course chemotherapy: A controlled study of indirect default retrieval method, Ind J Tub, 40, 185
Cited by
Chakaya, J., Khan, M., Ntoumi, F., Aklillu, E., Fatima, R., Mwaba, P., Kapata, N., Mfinanga, S., Hasnain, S. E., Katoto, P. D. M. C., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.107 · Cited by 1,104
“An approach that is based on providing omprehensive and individualized support to people being treated or TB is more likely to be acceptable to people with TB and their amilies and has been associated with better treatment completion ates (Alipanah et al., 2018).”
BackgroundTreatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
“compared with health facility–based DOT or self-administered therapy (11, 39).”
MethodSelf-citationDheda, K., Perumal, T., Moultrie, H., Perumal, R., Esmail, A., Scott, A. J., Udwadia, Z., Chang, K. C., Peter, J., Pooran, A., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00092-3 · Cited by 292
“140 Lessons learned in design, technological application, testing and fast-tracking of clinical trials, funding, development, and distribution of the SARS-CoV-2 vaccines could also be applied to accelerate tuberculosis vaccine development.”
BackgroundStrategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries
Godman, B., Egwuenu, A., Haque, M., Malande, O. O., Schellack, N., Kumar, S., Saleem, Z., Sneddon, J., Hoxha, I., Islam, S., et al. (2021) · Life · doi:10.3390/life11060528 · Cited by 237
Subbaraman, R., Nathavitharana, R. R., Mayer, K. H., Satyanarayana, S., Chadha, V. K., Arinaminpathy, N., & Pai, M. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002754 · Cited by 211
Clinical standards for the assessment, management and rehabilitation of post-TB lung disease
Migliori, G. B., Marx, F. M., Ambrosino, N., Zampogna, E., Schaaf, H. S., van der Zalm, M. M., Allwood, B., Byrne, A. L., Mortimer, K., Wallis, R. S., et al. (2021) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.21.0425 · Cited by 194
Self-citationTrajman, A., Campbell, J. R., Kunor, T., Ruslami, R., Amanullah, F., Behr, M. A., & Menzies, D. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02479-6 · Cited by 174
Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis
Chaves Torres, N. M., Quijano Rodríguez, J. J., Porras Andrade, P. S., Arriaga, M. B., & Netto, E. M. (2019) · PLOS ONE · doi:10.1371/journal.pone.0226507 · Cited by 171
Ledesma, J. R., Ma, J., Zhang, M., Basting, A. V. L., Chu, H. T., Vongpradith, A., Novotney, A., LeGrand, K. E., Xu, Y. Y., Dai, X., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00007-0 · Cited by 146
“…research has indicated that treatment adherence interventions (eg, patient counselling and education, reminders, and digital health technologies) 47,48 and social protection interventions (eg, cash transfers and economic incentives) 49,50 can increase treatment adherence and prevent mortality.”
Ruiz-Grosso, P., Cachay, R., de la Flor, A., Schwalb, A., & Ugarte-Gil, C. (2020) · PLOS ONE · doi:10.1371/journal.pone.0227472 · Cited by 134
“DOTS program refers to an approach to the delivery of antibiotic treatment in which health personnel observe patients taking their medication daily or three times per week, this approach has been found more effective when compared to self-administered therapy [6].”
Tran, S., Smith, L., El-Den, S., & Carter, S. (2022) · JMIR mHealth and uHealth · doi:10.2196/30671 · Cited by 121
“The concept of financial incentives tries to mitigate the cost associated with medications and reinforces positive behavior [13,14].”
BackgroundClosing gaps in the tuberculosis care cascade: an action-oriented research agenda
Subbaraman, R., Jhaveri, T. A., & Nathavitharana, R. R. (2020) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2020.100144 · Cited by 148
“Systematic reviews have evaluated studies on TB treatment outcomes to understand reasons for mortality [75], medication non-adherence [4], and interventions to improve adherence and reduce loss to follow-up [8].”
BackgroundRamalingam, S., Graham, C., Dove, J., Morrice, L., & Sheikh, A. (2019) · Scientific Reports · doi:10.1038/s41598-018-37703-3 · Cited by 110
“The amount of salt used could also be measured at the end of the study.”
BackgroundVernon, A., Fielding, K., Savic, R., Dodd, L., & Nahid, P. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002884 · Cited by 104
“Evidence for the benefit of traditional DOT has not been entirely consistent, and its role remains controversial [18,31,32].”
BackgroundSelf-citationBrowne, S. H., Umlauf, A., Tucker, A. J., Low, J., Moser, K., Gonzalez Garcia, J., Peloquin, C. A., Blaschke, T., Vaida, F., & Benson, C. A. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002891 · Cited by 87
Simonsmeier, B. A., Flaig, M., Simacek, T., & Schneider, M. (2022) · Health Psychology Review · doi:10.1080/17437199.2021.1967184 · Cited by 81
Tuberculosis Treatment Outcome and Predictors in Africa: A Systematic Review and Meta-Analysis
Teferi, M., El‐Khatib, Z., Boltena, M. T., Tarekegn, A., Asamoah, B. O., Biru, M., & Taye, H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182010678 · Cited by 90
“This finding suggests that evidence-based integrated interventions, such as patient education and counseling, incentives and enablers, establish reminders and tracer platforms, and digital health technologies need to be applied to improve TB treatment success [56,63].”
BackgroundInadequate housing and pulmonary tuberculosis: a systematic review
Lee, J.-Y., Kwon, N., Goo, G.-Y., & Cho, S. (2022) · BMC Public Health · doi:10.1186/s12889-022-12879-6 · Cited by 128
“, directly observed therapy), reminders and traces, incentives and enablers, patient education, digital technologies, staff education, and combinations of these interventions” [57].”
BackgroundAbolhassani-Chimeh, R., Gafar, F., Pradipta, I. S., Akkerman, O. W., Hak, E., Alffenaar, J.-W. C., & van Boven, J. F. M. (2020) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.19.0754 · Cited by 86
Pulmonary delivery of rifampicin-loaded soluplus micelles against Mycobacterium tuberculosis
Grotz, E., Tateosian, N. L., Salgueiro, J., Bernabeu, E., González, L., Manca, M. L., Amiano, N. O., Valenti, D., Manconi, M., García, V., et al. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101170 · Cited by 75
Clinical standards for the dosing and management of TB drugs
Alffenaar, J. C., STOCKER, S. L., Forsman, L. D., Garcia‐Prats, A. J., Heysell, S. K., Aarnoutse, R. E., Akkerman, O. W., Aleksa, A., van Altena, R., de Oñata, W. A., et al. (2022) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.22.0188 · Cited by 76
Liu, X., Thompson, J., Dong, H., Sweeney, S., Li, X., Yuan, Y., Wang, X., He, W., Thomas, B., Xu, C., et al. (2023) · The Lancet Global Health · doi:10.1016/s2214-109x(23)00068-2 · Cited by 69
Musiimenta, A., Tumuhimbise, W., Mugaba, A. T., Muzoora, C. K., Armstrong-Hough, M. J., Bangsberg, D. R., Davis, J. L., & Haberer, J. E. (2019) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2019.100119 · Cited by 73
“Enabling effective administration of TB therapy remains challenging [4].”
BackgroundKwon, B. S., Kim, Y., Lee, S. H., Lim, S. Y., Lee, Y. J., Park, J. S., Cho, Y., Yoon, H. I., Lee, C., & Lee, J. H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236109 · Cited by 68
Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment
Stephanie, F., Saragih, M., & Tambunan, U. S. F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050592 · Cited by 73
Bao, Y., Wang, C., Xu, H., Lai, Y., Yan, Y., Ma, Y., Yu, T., & Wu, Y. (2022) · JMIR Public Health and Surveillance · doi:10.2196/34277 · Cited by 88
“Public health programs have used various interventions to improve the self-management level of patients with TB, especially with regard to their adherence to TB treatment [5].”
Thekkur, P., Kumar, A. M. V., Chinnakali, P., Selvaraju, S., Bairy, R., Singh, A. R., Nirgude, A. S., Selvaraj, K., Venugopal, V., & Shastri, S. G. (2019) · Global Health Action · doi:10.1080/16549716.2019.1568826 · Cited by 61
Challenges and Opportunities for Global Genomic Surveillance Strategies in the COVID-19 Era
Ling-Hu, T., Rios-Guzman, E., Lorenzo-Redondo, R., Ozer, E. A., & Hultquist, J. F. (2022) · Viruses · doi:10.3390/v14112532 · Cited by 70
Appiah, M. A., Arthur, J. A., Gborgblorvor, D., Asampong, E., Kye-Duodu, G., Kamau, E. M., & Dako‐Gyeke, P. (2023) · BMC Public Health · doi:10.1186/s12889-023-16259-6 · Cited by 56
“Low adherence to TB medication increases the risk of prolonging infectiousness, relapse, and development or amplification of drug-resistant TB [7, 8].”
BackgroundPark, S., Sentissi, I., Gil, S. J., Park, W.-S., Oh, B., Son, A. R., Kong, Y. J., Park, S., Paek, E., Park, Y. J., et al. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16030412 · Cited by 64
“There have only been a few reports about electronic TB treatment adherence devices, most with a small number of enrolled patients [14].”
BackgroundMethodInfluentialCraciun, O., Torres, M. D. R., Llanes, A. B., & Romay‐Barja, M. (2023) · Journal of Tropical Medicine · doi:10.1155/2023/1014666 · Cited by 52
“Despite the fact that most of the cases are found in South-East Asia, most systematic reviews about tuberculosis’ KAP surveys conducted in this region were addressed to healthcare workers [7, 8] while those addressed to the general population were focused on specifc issues such as stigma [9], adherence to treatment [1…”
BackgroundWagnew, F., Gray, D. J., Tsheten, T., Kelly, M., Clements, A., & Alene, K. A. (2023) · Nutrition Reviews · doi:10.1093/nutrit/nuad120 · Cited by 67
“8,9 This is a significant contributor to prolonged transmission of TB, amplification of drug resistance, hampered treat-ment success, and catastrophic economic effects, especially in the presence of comorbidities.”
BackgroundSekandi, J. N., Buregyeya, E., Zalwango, S. K., Dobbin, K. K., Atuyambe, L. M., Nakkonde, D., Turinawe, J., Tucker, E., Olowookere, S., Turyahabwe, S., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00175-2019 · Cited by 50
Izudi, J., Tamwesigire, I. K., & Bajunirwe, F. (2020) · BMC Public Health · doi:10.1186/s12889-020-08646-0 · Cited by 45
Burzynski, J. N., Mangan, J. M., Lam, C. K., Macaraig, M., Salerno, M. M., deCastro, B. R., Goswami, N. D., Lin, C. Y.-C., Schluger, N. W., Vernon, A. A., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.44210 · Cited by 54
Adisa, R., Ayandokun, T. T., & Ige, O. M. (2021) · BMC Public Health · doi:10.1186/s12889-021-10698-9 · Cited by 51
“Treatment adherence among TB patients is challenging given the complexity, modest tolerability and long duration of treatment regimen currently available for both drugsusceptible and drug-resistant TB [23, 26].”
BackgroundResultInfluentialHealth literacy and tuberculosis control: systematic review and meta-analysis
Chauhan, A. S., Parmar, M., Dash, G. C., Chauhan, S., Sahoo, K. C., Samantaray, K., Sharma, J., Mahapatra, P., & Pati, S. (2024) · Bulletin of the World Health Organization · doi:10.2471/blt.23.290396 · Cited by 79
“44 Nonadherence has also been reported as a risk factor for drug-resistant tuberculosis.”
BackgroundQuality of life, tuberculosis and treatment outcome; a case–control and nested cohort study
Datta, S., Gilman, R. H., Montoya, R., Cruz, L. Q., Valencia, T. R., Huff, D., Saunders, M. J., & Evans, C. A. (2020) · European Respiratory Journal · doi:10.1183/13993003.00495-2019 · Cited by 47
“We also recommend supplementary socioeconomic support, which can further increase the likelihood of successful treatment, helping to return QOL to the community average [24, 25].”
Manyazewal, T., Woldeamanuel, Y., Holland, D. P., Fekadu, A., Blumberg, H. M., & Marconi, V. C. (2020) · Trials · doi:10.1186/s13063-020-04324-z · Cited by 44
Verhagen, L. M., Groot, R. D., Lawrence, C., Taljaard, J., Cotton, M. F., & Rabie, H. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.07.069 · Cited by 51
“Previous examples include mobile phone-based communication for HIV and tuberculosis diagnosis and management (Free et al., 2013; Sutcliffe et al., 2017; Alipanah et al., 2018; Gross et al., 2019).”
BackgroundZimmer, A., Heitkamp, P., Malar, J., Dantas, C. M. L., O'Brien, K., Pandita, A., & Waite, R. C. (2021) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2021.100248 · Cited by 55
Salcedo, J., Rosales, M., Kim, J. S., Nuno, D., Suen, S.-C., & Chang, A. H. (2021) · PLOS ONE · doi:10.1371/journal.pone.0254950 · Cited by 41
A Saudi Arabian Public Health Perspective of Tuberculosis
Saati, A. A., Khurram, M., Faidah, H. S., Haseeb, A., & Iriti, M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910042 · Cited by 47
Long term management of people with post-tuberculosis lung disease
Seo, W., Kim, H. W., Kim, J. S., & Min, J. (2024) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2023.395 · Cited by 70
Maynard, C., Tariq, S., Sotgiu, G., Migliori, G. B., van den Boom, M., & Field, N. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102057 · Cited by 44
“2,3,19 Studies of interventions not directly aimed at people with TB, for example training for healthcare workers, were excluded.”
BackgroundWei, X., Hicks, J. P., Zhang, Z., Haldane, V. E., Pasang, P., Li, L., Yin, T., Zhang, B., Li, Y., Pan, Q., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02270-5 · Cited by 53
Wang, N., Zhang, H., Zhou, Y., Jiang, H., Dai, B., Sun, M., Li, Y., Kinter, A., & Huang, F. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4521-2 · Cited by 40
“Second, the study lacked costeffectiveness and intervention impact analyses, which would yield essential information for considering large-scale use of the EMM [26].”
BackgroundDigital Health Interventions to Enhance Tuberculosis Treatment Adherence: Scoping Review
Lee, S., Rajaguru, V., Baek, J. S., Shin, J., & Park, Y. (2023) · JMIR mhealth and uhealth · doi:10.2196/49741 · Cited by 61
“Since low adherence increases the risk of poor treatment outcomes, several interventions have been attempted to enhance TB medication adherence [2].”
BackgroundCombating antimicrobial resistance in malaria, HIV and tuberculosis
Duffey, M., Shafer, R. W., Timm, J., Burrows, J. N., Fotouhi, N., Cockett, M. I., & Leroy, D. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00933-4 · Cited by 46
“Poor adherence to TB medication remains a major contributor to negative treatment outcomes, particularly in resource-constrained settings 119 .”
A randomised controlled trial to evaluate a medication monitoring system for TB treatment
Acosta, J., Flores, P., Alarcón, M., Grande-Ortiz, M., Moreno-Exebio, L., & Puyen, Z. M. (2022) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.21.0373 · Cited by 37
Oh, A. L., Makmor‐Bakry, M., Islahudin, F. H., & Wong, I. C. K. (2023) · BMJ Global Health · doi:10.1136/bmjgh-2022-010592 · Cited by 37
To End TB, First-Ever High-Level Meeting on Tuberculosis Must Address Stigma
Daftary, A., Mitchell, E. M. H., Reid, M. J. A., Fekadu, E., & Goosby, E. (2018) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.18-0591 · Cited by 50
Tadesse, A. W., Mohammed, Z., Foster, N., Quaife, M., McQuaid, C. F., Levy, J., van Kalmthout, K., van Rest, J., Jerene, D., Abdurhman, T., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06833-x · Cited by 37
Mussie, K. M., Yimer, S. A., Manyazewal, T., & Gradmann, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224277 · Cited by 35
“DR-TB remains a public health crisis and a major health security threat worldwide [5,6].”
BackgroundAdvances in clinical trial design: Weaving tomorrow’s TB treatments
Lienhardt, C., Nunn, A., Chaisson, R. E., Vernon, A. A., Zignol, M., Nahid, P., Delaporte, É., & Kasaeva, T. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003059 · Cited by 36
“This underscores the importance of the quality of execution in noninferiority trials, as differential adherence across treatment arms could lead to erroneous conclusions about treatment efficacy [39,45].”
BackgroundSelf-citationRyuk, D. K., Pelissari, D. M., Alves, K. B. A., Oliveira, P. B., Castro, M. C., Cohen, T., Sanchez, M. N., & Menzies, N. A. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09417-7 · Cited by 31
“It is possible these relationships are not consistent across Brazil, as the approach to providing DOT differ at the state level [17, 18].”
BackgroundRobsky, K., Hughes, S., Kityamuwesi, A., Kendall, E. A., Kitonsa, P. J., Dowdy, D. W., & Katamba, A. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05099-z · Cited by 30
Pontali, E., Silva, D. R., Marx, F. M., Caminero, J. A., Centis, R., D’Ambrosio, L., García-García, J.-M., Muhwa, J. C., Tiberi, S., & Migliori, G. B. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2022.05.010 · Cited by 36
Patient-perceived treatment burden of tuberculosis treatment
Ting, N. C. H., El-Turk, N., Chou, M. S. H., & Dobler, C. C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241124 · Cited by 29
“In other studies, treatment completion rates have been shown to be similar for video DOT and clinic-based DOT [23].”
Bröckelmann, N., Balduzzi, S., Harms, L., Beyerbach, J., Πετροπούλου, Μ., Kubiak, C., Wolkewitz, M., Meerpohl, J. J., & Schwingshackl, L. (2022) · BMC Medicine · doi:10.1186/s12916-022-02369-2 · Cited by 34
“Alipanah 2018 [24] Self-administered therapy All-cause mortality 4 RR: 0.”
BackgroundMethodInfluentialMarley, G., Zou, X., Nie, J., Cheng, W., Xie, Y., Liao, H., Wang, Y., Tao, Y., Tucker, J. D., Sylvia, S., et al. (2023) · PLOS Medicine · doi:10.1371/journal.pmed.1004091 · Cited by 28
Sekandi, J. N., Shi, W., Zhu, R., Kaggwa, P., Mwebaze, E., & Li, S. (2023) · JMIR AI · doi:10.2196/40167 · Cited by 38
“The existing interventions to mitigate poor medication adherence have limited effectiveness for a variety of reasons [5].”
Zhou, J., Pu, J., Wang, Q., Zhang, R., Liu, S., Wang, G., Zhang, T., Chen, Y., Xing, W., Liu, J., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-053797 · Cited by 31
Zelnick, J., Daftary, A., Hwang, C., Labar, A. S., Boodhram, R., Maharaj, B., Wolf, A., Mondal, S., Amico, K. R., Orrell, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1557 · Cited by 29
Impact of mental disorders on active TB treatment outcomes: a systematic review and meta-analysis
Lee, G. E., Scuffell, J., Galea, J. T., Shin, S. S., Magill, E., Jaramillo, E., & Sweetland, A. C. (2020) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.20.0458 · Cited by 37
Self-citationPark, H., Cheon, H.-B., Choi, S. H., & Kwon, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.659675 · Cited by 27
“reported that increased adherence to TB treatment directly affects the improvement of treatment outcomes through an extensive systematic review (Alipanah et al., 2018).”
BackgroundA review of mobile health interventions for public private mix in tuberculosis care
Tumuhimbise, W., & Musiimenta, A. (2021) · Internet Interventions · doi:10.1016/j.invent.2021.100417 · Cited by 31
Lungu, P., Kerkhoff, A. D., Kasapo, C. C., Mzyece, J., Nyimbili, S., Chimzizi, R. B., Silumesii, A., Kagujje, M., Subbaraman, R., Muyoyeta, M., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-044867 · Cited by 27
Chapter 5: Treatment of tuberculosis disease
Johnston, J. C., Cooper, R. D., & Menzies, D. (2022) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2022.2036504 · Cited by 31
Jerene, D., Levy, J., van Kalmthout, K., Rest, J. V., McQuaid, C. F., Quaife, M., Charalambous, S., Gamazina, K., Garfin, A. M. C., Mleoh, L., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068685 · Cited by 27
Survival analysis of patients with tuberculosis in Erbil, Iraqi Kurdistan region
Balaky, S. T. J., Mawlood, A. H., & Shabila, N. P. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4544-8 · Cited by 27
Wang, N., Shewade, H. D., Thekkur, P., Zhang, H., Yuan, Y., Wang, X., Wang, X., Sun, M., & Huang, F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242112 · Cited by 26
“TB treatment outcomes improved with the use of adherence interventions when compared to DOT or SAT alone [3].”
MethodResultClinical standards for drug-susceptible pulmonary TB
Akkerman, O. W., Duarte, R., Tiberi, S., Schaaf, H. S., Lange, C. G., Alffenaar, J. C., Denholm, J. T., Carvalho, A. C. C., Bolhuis, M. S., Borisov, S. E., et al. (2022) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.22.0228 · Cited by 26
Jerene, D., van Kalmthout, K., Levy, J., Alacapa, J., Deyanova, N., Dube, T., Mganga, A., Tasca, B. G., Bogdanov, A., Efo, E., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02847-2 · Cited by 42
Alinaitwe, B., Shariff, N. J., & Boddupalli, B. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-96260-8 · Cited by 51
“Given that poor adherence has been associated with several complications 35 , a considerable proportion of patients in our study is at risk of treatment failure, developing drug-resistant TB, and likely to stay infectious for a longer duration, thus complicating the TB epidemic in Uganda.”
Bhatnagar, H. (2019) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2019.100127 · Cited by 30
“The scale-up and institutionalization of effective digital innovations, such as 99DOTS and videoDOTS, may also promote the user-friendliness of DOTS [123,149,150].”
BackgroundJang, K.-S., Oh, J.-E., & Jeon, G. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191610191 · Cited by 23
“In addition, most previous intervention studies examine medication education and medication compliance, and while some studies examined psychological counseling intervention for improving patients’ adherence to tuberculosis medication [7,10].”
BackgroundFekadu, G., Jiang, X., Yao, J., & You, J. H. S. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.10.029 · Cited by 23
“A systematic review and meta-analysis on he association between adherence interventions and TB treatment utcomes found that the use of directly observed therapy (DOT) as significantly associated with improved treatment outcomes Alipanah et al., 2018 ).”
InfluentialShringarpure, K. S., Gurumurthy, M., Sagili, K. D., Taylor, M., Garner, P., Tonsing, J., Rao, R., & Sachdeva, K. S. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-063926 · Cited by 28
Thompson, R. R., Kityamuwesi, A., Kuan, A., Oyuku, D., Tucker, A., Ferguson, O., Kunihira Tinka, L., Crowder, R., Turyahabwe, S., Cattamanchi, A., et al. (2022) · Value in Health · doi:10.1016/j.jval.2021.12.002 · Cited by 22
“Staff $47 (2-84) $651 $3711 (2304-5603) $3711 (2304-5603)”
Practical management of suspected hypersensitivity reactions to anti‐tuberculosis drugs
Bermingham, W. H., Bhogal, R., Nagarajan, S. A., Mutlu, L. K., Shabrawy, R. M. E., Madhan, R., Krishnaswamy, U. M., Murali, M. R., Kudagammana, S. T., Shrestha, R., et al. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.14084 · Cited by 22
Video-Observed Therapy Versus Directly Observed Therapy in Patients With Tuberculosis
Truong, B., Tanni, K. A., & Qian, J. (2021) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2021.10.013 · Cited by 22
Cost-effectiveness of a medication event monitoring system for tuberculosis management in Morocco
Yang, J., Kim, H., Park, S., Sentissi, I., Green, N., Oh, B., Kim, Y., Oh, K. H., Paek, E., Park, Y. J., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267292 · Cited by 22
Jiang, Y., Chen, J., Ying, M., Liu, L., Li, M., Lu, S., Li, Z., Zhang, P., Xie, Q., Liu, X., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1136094 · Cited by 22
Clinical standards for drug-susceptible TB in children and adolescents
Chiang, S. S., Graham, S. M., Schaaf, H. S., Marais, B. J., Sant’Anna, C. C., Sharma, S., Starke, J. R., Triasih, R., Achar, J., Amanullah, F., et al. (2023) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.23.0085 · Cited by 28
Garcia‐Cremades, M., Solans, B. P., Strydom, N., Vrijens, B., Pillai, G. C., Shaffer, C., Thomas, B. V., & Savić, R. M. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-041921-074800 · Cited by 26
Rohit, A., Kumar, A. M. V., Thekkur, P., Shastri, S. G., Kumar, R., Nirgude, A. S., Reddy, M. M., Ravichandra, C., Narasimhaiah, S., & Balu, P. S. (2020) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_474_20 · Cited by 21
“Systematic reviews show that cash incentives are beneficial in improving the treatment adherence and treatment success rate.[8-10]”
BackgroundTuberculosis treatment within differentiated service delivery models in global HIV/TB programming
Tran, C. H., Moore, B. K., Pathmanathan, I., Lungu, P., Shah, N. S., Oboho, I., Al‐Samarrai, T., Maloney, S. A., Date, A. A., & Boyd, A. T. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25809 · Cited by 21
Medina‐Marino, A., Bezuidenhout, D., Ngcelwane, N., Cornell, M., Wainberg, M. L., Beyrer, C., Bekker, L., & Daniels, J. (2022) · American Journal of Men s Health · doi:10.1177/15579883221129349 · Cited by 23
“This is highlighted by a 2018 meta-analysis of 129 TB adherence interventions, of which no male-centered interventions were identified, and only a limited proportion (n = 34) disaggregated their results by sex (Alipanah et al., 2018).”
BackgroundMethodInfluentialde Lima, L. V., Pavinati, G., Palmieri, I. G. S., Vieira, J. P., Blasque, J. C., Higarashi, I. H., Fernandes, C. A. M., & Magnabosco, G. T. (2023) · Revista gaúcha de enfermagem · doi:10.1590/1983-1447.2023.20230077.en · Cited by 21
“…this, DOT is a strategy that has been implemented worldwide and shown effectiveness in results, leading to improved adherence to treatment and, thus, reducing unfavorable outcomes in people affected by TB, as demonstrated in studies conducted in Brazil, England, United States and Ethiopia (21–24) .”
de Oliveira, M. C. B., Sant’Anna, C. C., Luiz, R. R., & Kritski, A. L. (2020) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.20-0209 · Cited by 21
Du, L., Wu, R., Chen, X., Xu, J. Y., Ji, H., & Zhou, L. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s277650 · Cited by 20
Iribarren, S., Milligan, H., Chirico, C., Goodwin, K., Schnall, R., Telles, H., Iannizzotto, A., Sanjurjo, M., Lutz, B. R., Pike, K., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100291 · Cited by 39
“38 Similarly, findings from another systematic review of patient’s perceptions of mHealth apps found users stressed the ability to tailor prompts to their need.”
BackgroundOpperman, M., & du Preez, I. (2022) · African Journal of Infectious Diseases · doi:10.21010/ajidv17i1.6 · Cited by 31
“categories, namely: (1) socio-demographic factors, (2) patient-related factors, (3) TB disease and other health-related factors, (4) healthcare and system determinants, and (5) treatment-related factors (WHO, 2003).”
BackgroundBogale, L., Tsegaye, T., Abdulkadir, M., & Akalu, T. Y. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s300814 · Cited by 19
“Treatment failure, death, and LTFU were considered unfavorable treatment outcomes.(2) According to the 2017 global report, 558,000 people developed active TB.”
BackgroundMakabayi‐Mugabe, R., Musaazi, J., Zawedde‐Muyanja, S., Kizito, E., Namwanje, H., Aleu, P., Charlet, D., Lopez, D. B. F., Brightman, H., Turyahabwe, S., et al. (2022) · BMC Health Services Research · doi:10.1186/s12913-021-07365-5 · Cited by 20
“However, delivery of care through health facility-based directly observed therapy (HFDOT) has been documented to significantly contribute to poor treatment outcomes particularly in resource limited settings [5].”
BackgroundStephanie, F., Tambunan, U. S. F., & Siahaan, T. J. (2022) · Life · doi:10.3390/life12111774 · Cited by 23
“Due to these problems, the effort to discover a novel antitubercular drug with a shorter treatment regimen is imperative [11].”
BackgroundMohamed, M. S., Zary, M., Kafie, C., Chilala, C. I., Bahukudumbi, S., Foster, N., Gore, G. C., Fielding, K., Subbaraman, R., & Schwartzman, K. (2024) · medRxiv · doi:10.1101/2024.01.31.24302115 · Cited by 19
Mohamed, M. S., Zary, M., Kafie, C., Chilala, C. I., Bahukudumbi, S., Foster, N., Gore, G. C., Fielding, K., Subbaraman, R., & Schwartzman, K. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11503-3 · Cited by 46
“These findings are concordant with previous reviews [8, 14, 96].”
Improving Treatment Adherence with Integrated Patient Management for TB Patients in Morocco
Park, S., Moon, N., Oh, B., Park, M., Kang, K., Sentissi, I., & Bae, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18199991 · Cited by 18
Metadata
- Authors
- Alipanah, N., Jarlsberg, L., Miller, C., Linh, N. N., Falzon, D., Jaramillo, E., & Nahid, P.
- Affiliations
- University of California, San Francisco (US)
- World Health Organization (CH)
- Corresponding author
- Nahid, Payam
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-07-03
- Volume
- 15
- Issue
- 7
- Pages
- e1002595
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC6029765
- OpenAlex
- W2810683857
- Cited by
- 503
- References
- 156
- Citations by year
- 2026: 48 · 2025: 75 · 2024: 79 · 2023: 88 · 2022: 75 · 2021: 67 · 2020: 42 · 2019: 26 · 2018: 3
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (publishedVersion)
- eScholarship (California Digital Library) (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
- Keywords
- tuberculosis, medication adherence, directly observed therapy, drug-resistant tuberculosis, self-administered therapy, sputum smear conversion, treatment failure, drug resistance development, incentives, patient education, video-observed therapy, mobile phone reminders, treatment success, relapse, transmission risk, multidrug therapy, patient-provider relationship
- MeSH terms
- Adolescent, Adult, Antitubercular Agents, Attitude of Health Personnel, Child, Child, Preschool, Health Personnel, Humans, Infant, Infant, Newborn, Health Knowledge, Attitudes, Practice, Patient Education as Topic, Risk Factors, Self Care, Tuberculosis, Video Recording, Randomized Controlled Trials as Topic, Treatment Outcome, Telemedicine, Directly Observed Therapy, Cell Phone, Medication Adherence, Text Messaging, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.